CYTOMEGALOVIRUS INFECTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE CHANGE IN CLINICAL PICTURE, DIAGNOSIS, AND TREATMENT MODALITY

Cytomegalovirus (CMV) infection takes an important place as a major cause of morbidity and mortality after hematopoietic stem cell transplantation. There have been significant advances in understanding the pathogenesis of CMV, early detection of virus by modern laboratory technics, and conformable antiviral treatment. In this work, determination of high risk stem cell recipients for CMV infection and prophylactic (from the onset of engraftment until 100 days after transplantation) or preemptive (prevention of CMV disease after detection of CMV infection) treatment are reviewed in the context of important literature on this subject.